Similar companies
Income Statement (GBP)
| Q1 '26 | QoQ | |
|---|---|---|
| Gross Profit | -44,000 | 910.3% |
| Cost of Revenue | 44,000 | 910.3% |
| Operating expense | 195M | 13.2% |
| Net Income | -189M | 13.6% |
| EBITDA | -195M | 10.9% |
Balance Sheet (GBP)
| Q1 '26 | QoQ | |
|---|---|---|
| Total Assets | 491M | 11.9% |
| Total Liabilities | 77M | 12.8% |
| Total Equity | 414M | 15.3% |
| Shares Outstanding | 775M | 1.2% |
Cash Flow (GBP)
| Q1 '26 | QoQ | |
|---|---|---|
| Cash from operations | -93M | 22.6% |
| Cash from investing | -180,000 | 99.9% |
| Cash from financing | 2.9M | 99.3% |
EPS
Financial Highlights for Summit Therapeutics in Q1 '26
Gross Profit stood at -44,000, marking a -910.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 44,000, a 910.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 195M, showing a -13.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -189M, showing a 13.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -195M, showing a 10.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Summit Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
